Allakos reported encouraging phase 1 data. Onconova completed INSPIRE trial enrollment. Mylan hit by EpiPen safety issues again.
More Allakos Data, And Other News: The Good, Bad, And Ugly Of Biopharma Videos
Allakos Data, And Other News: The Good, Bad, And Ugly Of Biopharma
Allakos Data, And Other News: The Good, Bad, And Ugly Of Biopharma
Leave a reply